The global Colorectal Cancer (CRC) Drugs Market size is
expected to reach USD 10.8 billion by 2022, according to a new report by Grand
View Research, Inc., exhibiting a CAGR of 3.3% during the forecast period.
Several factors such as increasing target population and rising adoption of
targeted therapies are anticipated to fuel market growth.
Products in the pipeline are striving to meet some of the
unmet needs of the colorectal cancer (CRC) market. If approved, Array
Biopharma’s cetuximab plus encorafenib would become the first therapy indicated
for BRAF-mutant mCRC treatment. Sumitomo Dainippon’s Napabucasin is a cancer
stem cell inhibitor targeting STAT-3.
There are few available adjuvant/neoadjuvant medicines
for treatment of high-risk resectable colorectal cancer. Lack of pipeline
agents in this setting presents a good opportunity for development of effective
treatments that can improve cure rates for resected patients. At present, most
available treatments for resectable CRC include cheaper chemotherapeutic
regimens and generics.
Upcoming patent expiries of key products such as Roche’s
Avastin, Amgen’s Vectibix, and Sanofi’s Zaltrap will lead to biosimilar
penetration. Amgen/Allergan’s Mvasi marked the first Avastin biosimilar
approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and Krabeva
are some of the biosimilars to Avastin launched in India. Several other
biosimilars to Avastin and Erbitux are under development.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/colorectal-cancer-crc-drugs-therapeutic-market
Further key findings from the report
suggest:
- Immunotherapy dominated the market based on drug
class in 2016, owing to increasing adoption of targeted therapies such as
Avastin and Erbitux
- Chemotherapy is likely to lose market share on
account of non-specificity, adverse effects, and development of resistance
to chemical agents. However, recent launch of anti-PD1 drugs such as
Opdivo and Keytruda is likely to change the current landscape due to their
target-oriented mechanism of action
- U.S. accounted for the largest share based on
country and is projected to maintain its dominance through to 2022 owing
to growing disease burden, increasing treatment rate, and high cost of
drugs
- Roche led the colorectal cancer industrial setting
in 2016 due to growing usage of Avastin. Avastin was the highest
revenue-generating CRC medicine in 2016. However, Roche is projected to
lose market share on grounds of Avastin’s patent expiry and biosimilar
penetration
- Bristol-Myer Squibb and Merck are anticipated to be
market leaders in the colorectal cancer drugs market space by 2022 due to
increasing adoption of targeted therapies such as Opdivo and Keytruda.
Grand View Research has segmented the global colorectal
cancer drugs market based on drug class and country:
Colorectal Cancer Drug Class Outlook
(Revenue, USD Million, 2016 - 2022)
- Chemotherapy
- Immunotherapy
- Others
Colorectal Cancer Drugs Country Outlook
(Revenue, USD Million, 2016 - 2022)
- U.S.
- U.K.
- Germany
- Spain
- France
- Italy
- Japan
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment